{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "marketState": "PRE", "messageBoardId": "finmb_49371601", "regularMarketChangePercent": 4.153842, "regularMarketPrice": 0.01354, "exchange": "PNK", "shortName": "REBUS HLDGS INC", "longName": "Rebus Holdings, Inc.", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1257345000000, "priceHint": 4, "regularMarketChange": 0.00053999946, "regularMarketTime": 1684176705, "regularMarketDayHigh": 0.01354, "regularMarketDayRange": "0.0102 - 0.01354", "regularMarketDayLow": 0.0102, "regularMarketVolume": 19903, "regularMarketPreviousClose": 0.013, "fullExchangeName": "Other OTC", "financialCurrency": "USD", "regularMarketOpen": 0.0102, "averageDailyVolume3Month": 69804, "averageDailyVolume10Day": 229563, "fiftyTwoWeekLowChange": 0.00854, "fiftyTwoWeekLowChangePercent": 1.7080001, "fiftyTwoWeekRange": "0.005 - 0.0278", "fiftyTwoWeekHighChange": -0.01426, "fiftyTwoWeekHighChangePercent": -0.51294965, "fiftyTwoWeekLow": 0.005, "fiftyTwoWeekHigh": 0.0278, "dividendDate": 1593475200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.03, "sharesOutstanding": 32132900, "bookValue": -0.163, "fiftyDayAverage": 0.0127786, "fiftyDayAverageChange": 0.0007614, "fiftyDayAverageChangePercent": 0.05958399, "twoHundredDayAverage": 0.01355565, "twoHundredDayAverageChange": -1.5649945e-05, "twoHundredDayAverageChangePercent": -0.0011544961, "marketCap": 495321, "priceToBook": -0.083067484, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Inspyr Therapeutics, Inc.", "nameChangeDate": "2023-05-15", "tradeable": false, "cryptoTradeable": false, "displayName": "Rebus", "symbol": "RBSH"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "2629 Townsgate Road", "address2": "Suite 215", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "818 597 7552", "website": "https://www.rebus-corp.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Raul  Silvestre Esq.", "age": 51, "title": "CEO, CFO, Pres, Principal Accounting Officer & Director", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. John T. Isaacs Ph.D.", "title": "Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Samuel R. Denmeade M.D.", "title": "Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}